Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGAL as a Biomarker of Mineralocorticoid Receptor Activity
NCT02129621Completed
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- May 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of spironolactone in primary hyperaldosteronism (PA) (5 arms), sponsored by CHRU de Nancy - Hôpital Central. Primary endpoint: Lipocalin blood and urinary concentrations at 8 months. Started May 2010; status: completed.
02
Drugs
spironolactone
03
Conditions
primary hyperaldosteronism (PA)
Beyond the preview
Go deeper on NCT02129621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129621.